Hormone-Refractory Prostate Cancer
Hormone-refractory prostate cancer is a form of prostate cancer that continues to grow despite hormone therapy aimed at lowering testosterone levels, which is often used to manage the disease.
Prostate Cancer: VIR-5500 Treatment
We are studying the safety and early effects of VIR-5500 in men with prostate cancer. This trial aims to understand how well the treatment works and how it is processed in the body.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hospital Quironsalud Barcelona
Oncology
Barcelona, Spain
Hospital Universitari Vall D Hebron
Oncology
Barcelona, Spain
Clinica Universidad De Navarra
Oncology
Ciudad Lineal, Spain
Sponsor: Vir Biotechnology Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.